Prime Therapeutics will Include Biosimilars to the NetResults Formulary in Addition to Humira
Shots:
- Prime Therapeutics will include biosimilars alongside AbbVie’s rheumatoid arthritis drug Humira on its preferred list of drugs, the NetResults formulary. The decision is expected early in 2023 incl. 8 biosimilars referencing Humira are expected to be launched with Amgen’s Amjevita
- Humira is used for the treatment of RA, CD, and other diseases. The use of biosimilars will deliver the lowest net cost options & helps ensure optimal, cost-effective therapy for complex inflammatory conditions
- Fresenius Kabi’s adalimumab biosimilar Idacio referencing Humira was approved in Dec 2022 & expected to be launched after July 2023
Ref: PRNewswire | Image: Prime Therapeutics
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
